Otilonium bromide in irritable bowel syndrome: a dose-ranging randomized double-blind placebo-controlled trial.


AIM To examine the efficacy and safety of otilonium bromide (OB) in treatment-sensitive functional irritable bowel syndrome (IBS) clinical parameters. METHODS Ninety-three patients (44.8 ± 12.6 years, 69% female) with IBS symptoms complying with Rome II criteria participated in this double-blind, placebo-controlled, randomised, dose-ranging phase I/II… (More)
DOI: 10.3748/wjg.v20.i34.12283


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.


Citations per Year

Citation Velocity: 7

Averaging 7 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.

Slides referencing similar topics